目前仍缺乏对2型糖尿病（T2DM）对非小细胞肺癌（NSCLC）代谢状态的确切影响的全面了解。本研究探讨了 NSCLC 和 T2DM 共存患者与 NSCLC 患者相比肿瘤组织的代谢变化。采用临床分析和代谢组学相结合的方法，包括 20 名 NSCLC 患者和 20 名 NSCLC T2DM 患者。使用液相色谱-质谱（LC-MS）方法对肿瘤组织进行靶向代谢组学分析。在正交偏最小二乘判别分析 (OPLS-DA) 中，观察到 NSCLC T2DM 和匹配的 NSCLC 组织样本之间存在明显的分离。此外，还发现糖尿病/非糖尿病肿瘤组织样本中 7 种代谢物的水平存在显着差异。相关途径包括精氨酸生物合成、谷胱甘肽代谢、精氨酸和脯氨酸代谢、嘌呤代谢、生物素代谢和组氨酸代谢。 3-苯乳酸、肉碱-C5、肉碱-C12和血清素与NSCLC患者的空腹血糖水平呈正线性相关。尿苷、哌可酸、胞嘧啶和空腹血糖水平被发现呈负相关。我们的结果表明，与单纯 NSCLC 患者相比，并发 T2DM 的 NSCLC 患者的肿瘤组织表现出明显的代谢变化。

A comprehensive understanding of the exact influence of type 2 diabetes mellitus (T2DM) on the metabolic status of non-small cell lung cancer (NSCLC) is still lacking. This study explores metabolic alterations in tumor tissues among patients with coexisting NSCLC and T2DM in comparison with NSCLC patients. A combined approach of clinical analysis and metabolomics was employed, including 20 NSCLC patients and 20 NSCLC+T2DM patients. Targeted metabolomics analysis was performed on tumor tissues using the liquid chromatography-mass spectrometry (LC-MS) approach. A clear segregation was observed between NSCLC+T2DM and matched NSCLC tissue samples in Orthogonal Partial Least Squares Discrimination Analysis (OPLS-DA). Furthermore, the levels of 7 metabolites are found to be significantly different between diabetes/nondiabetes tumor tissue samples. The related pathways included arginine biosynthesis, glutathione metabolism, arginine and proline metabolism, purine metabolism, biotin metabolism, and histidine metabolism. 3-Phenyllactic acid, carnitine-C5, carnitine-C12, and serotonin showed a positive linear correlation with fasting blood glucose levels in NSCLC patients. Uridine, pipecolic acid, cytosine, and fasting blood glucose levels were found to have a negative correlation. Our results suggest that NSCLC patients with concurrent T2DM exhibit distinct metabolic shifts in tumor tissues compared to those of solely NSCLC patients.